Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 11, Issue 5, 2005, Pages 481-487

  Mylonaki, Maria ^a   Rayment, Neil B ^b   Rampton, David S ^a   Hudspith, Barry N ^b   Brostoff, Jonathan ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bifidobacteria; Flourescent in situ hybridization; IBD; Rectal mucosa

Indexed keywords

ADULT; AGED; ARTICLE; BACTEROIDES; BIFIDOBACTERIUM; CLINICAL ARTICLE; CLOSTRIDIA; COLON FLORA; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; ESCHERICHIA COLI; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; INTESTINE CRYPT; LACTOBACILLUS; PRIORITY JOURNAL; RECTUM BIOPSY; RECTUM MUCOSA; ULCERATIVE COLITIS;

ADULT; AGED; BACTEROIDES; BIFIDOBACTERIUM; CASE-CONTROL STUDIES; CLOSTRIDIUM; COLITIS, ULCERATIVE; COLONOSCOPY; CROHN DISEASE; ESCHERICHIA COLI; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTESTINAL MUCOSA; LACTOBACILLUS; MALE; MIDDLE AGED; RECTUM; RNA;

EID: 18944382323     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MIB.0000159663.62651.4f     Document Type: Article

References (34)

1. Burke DA, Axon ATR. Ulcerative colitis and Escherichia coli with adhesive properties. J Clin Pathol. 1987;40:782-786.
2. Burke DA, Axon ATR. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ. 1988;297:102-104.
3. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology. 1999;116:1246-1249.
4. Parthmakanthan S, Thornley JP, Hawkey CJ. Mucosally associated bacterial flora of the human colon: quantitative and species specific differences between normal and inflamed colonic biopsies. Microb Ecol Health Dis. 1999;11:169-174.
5. Walmsley RS, Anthony A, Slim R, et al. Absence of Escherichia coli, Listeria monocytogenes and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues. J Clin Pathol. 1998;51:657-661.
6. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44-54.
7. Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut. 1992;33:646-650.
8. Gillian H, Hudson MJ, Swarbrick ET, et al. Adhesive and hydrophbic properties of Escherichia coli from the rectal mucosa of patients with ulcerative colitis. Gut. 1993;34:63-67.
9. Schultsz C, Van Den Berg FM, Ten Kate FW, et al. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology. 1999;117: 1089-1097.
10. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal changes in proctocolitis. BMJ. 1964;1:189-192.
11. Poxton IR, Brown R, Sawyerr A, et al. Mucosa-associated bacterial flora of the human colon. J Med Microbiol. 1997; 46:85-91.
12. Giaffer MH, Holdsworth CD, Duerden BI. The assessment of fecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol. 1991;35:238-243.
13. Favier C, Neut C, Mizon C, et al. Fecal beta-D-galactosidase production and bifidobacteria are decreased in Crohn's disease. Dig Dis Sci. 1997;42: 817-822.
14. Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the dominant bacterial groups in patients with Crohn's disease of the colon. Gut. 2003; 52:237-243.
15. Rayment N, Mylonaki M, Rampton D, et al. Co-localisation of E. coli with macrophages in lamina propria in patients with active inflammatory bowel disease (IBD)). Gut. 2003;Suppl 1:A13.
16. Rayment N, Miller RF, Ali N, et al. Synthesis of tumor necrosis factor-alpha mRNA in bronchoalveolar lavage cells from human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia. J Infect Dis. 1996;174:654-659.
17. Von Wulffen H, Russmann H, Karch H, et al. Verocytotoxin-producing Escherichia coli O2:H5 isolated from patients with ulcerative colitis. Lancet. 1989;1:1449-1559.
18. Schultsz C, Moussa M, Van Ketel R, et al. Frequency of pathogenic and enteroadherent Escherichia coli in patients with inflammatory bowel disease and controls. J Clin Pathol. 1997;50:573-579.
19. Matsuda H, Fujiyama Y, Andoh A, et al. Characterization of antibody-responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol. 2000;15:61-68.
20. Fabia R, Ar'Rajab A, Johannson ML, et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion. 1993;54:248-255.
21. Pitcher MC, Beatty ER, Cummings JH. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulfide in patients with ulcerative colitis. Gut. 2000;46:64-72.
22. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology. 1999;116: 1107-1114.
23. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut. 2001;48:132-135.
24. Farina C, Caprioli A, Luzzi I, et al. Ulcerative colitis precipitated by a verocytotoxin-producing Escherichia coli infection. Ital J Gastroenterol. 1995;27:498-500.
25. Burke DA, Axon AT, Clayden SR, et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Therap. 1990;4:123-129.
26. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Therap. 1997;11:853-859.
27. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-639.
28. Sartor RB. Colitis in HLA-B27/beta 2 microglobulin transgenic rats. Int Rev Immunol. 2000;19:39-50.
29. O'Mahony L, Feeney M, O'Halloran S, et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Therap. 2001;15:1219-1225.
30. Caplan MS, Miller-Catchpole R, Kaup S, et al. Bifidobacterial supplementation reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Gastroenterology. 1999;117:577-583.
31. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind placebo-controlled trial. Gastroenterology. 2000;119:305-309.
32. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double blind placebo-controlled trial. Gastroenterology. 2003;124:1202-1209.
33. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Therap. 1999;13:1103-1108.
34. MacDonald TT, Pettersson S. Bacterial regulation of intestinal immune responses. Inflamm Bowel Dis. 2000;6:116-122.